Literature DB >> 2001010

Fatigue and recovery of rat soleus muscle are influenced by inhibition of an intracellular carbonic anhydrase isoform.

P Frémont1, H Riverin, J Frenette, P A Rogers, C Côté.   

Abstract

Carbonic anhydrase III (CA III; EC 4.2.1.1) is the most abundant cytosolic enzyme in type I skeletal muscle fibers. Methazolamide, a specific CA inhibitor, was used to characterize the effects of inhibiting CA III on the resistance to fatigue and recovery of the rat soleus muscle using a 60-min fatigue protocol performed in vitro at 25 degrees C. Incubation with 10(-3) M methazolamide resulted in a smaller decrease in tension production during the fatigue protocol, thereby increasing the total tension-time integral for the fatigue test. However, the rate and extent of recovery after the test were lower in the experimental group compared with the control group. A similar effect was observed at physiological temperature (35 degrees C). The results indicate that inhibition of CA III significantly influences tension production as early as 30 s into the stimulation protocol. Inhibition of CA III only during the recovery period did not influence the recovery profile, thereby indicating that the impaired recovery was related to the presence of methazolamide during the stimulation period.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2001010     DOI: 10.1152/ajpregu.1991.260.3.R615

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

1.  Physiologic, metabolic, and muscle fiber type characteristics of musculus uvulae in sleep apnea hypopnea syndrome and in snorers.

Authors:  F Sériès; C Côté; J A Simoneau; Y Gélinas; S St Pierre; J Leclerc; R Ferland; I Marc
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

2.  Mass spectrometry-based proteomic analysis of middle-aged vs. aged vastus lateralis reveals increased levels of carbonic anhydrase isoform 3 in senescent human skeletal muscle.

Authors:  Lisa Staunton; Margit Zweyer; Dieter Swandulla; Kay Ohlendieck
Journal:  Int J Mol Med       Date:  2012-07-06       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.